Jaguar Health Announces 1-for-35 Reverse Stock Split to Meet Nasdaq Listing Requirements
JAGX sits 16% above its 52-week low of $0.313.
Summary
Jaguar Health will effect a 1-for-35 reverse stock split on April 30, 2026, to comply with Nasdaq's minimum bid price rule, following an extension granted by the Nasdaq Hearings Panel.
Key Events · Corporate Governance and Compliance · JAGX
-
Reverse Stock Split Approved and Set
The Board of Directors approved a 1-for-35 reverse stock split, effective April 30, 2026, following shareholder approval of a reverse split range on April 20, 2026.
-
Nasdaq Delisting Threat Addressed
The Nasdaq Hearings Panel granted an extension until May 15, 2026, for the company to regain compliance with the $1.00 minimum bid price rule.
-
Continued Listing Conditions
To maintain listing, the company must achieve a closing bid price of at least $1.00 for 10 consecutive business days by May 15, 2026. The Panel retains jurisdiction until September 1, 2026.
Analysis · JAGX · Life Sciences
Jaguar Health is implementing a significant 1-for-35 reverse stock split to address its non-compliance with Nasdaq's minimum $1.00 bid price rule. While the Nasdaq Hearings Panel granted an extension until May 15, 2026, to regain compliance, the reverse split is a common tactic for distressed companies to avoid delisting. This action, while necessary for continued listing, often signals underlying financial challenges and can lead to further share price volatility and dilution concerns for investors. The company's 2025 annual report already highlighted severe financial distress and a going concern warning.
At the time of this filing, JAGX was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.31 to $15.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.